Implantable device maker Med-Ally locating operations in South Carolina

Implantable devicemaker Med-Ally is locating is operations in Berkeley County, near Charleston, South Carolina.

Med-Ally, the maker of active medical devices like the VersaStim neuromodulation platform, said it is moving its operations to Goose Creek in Berkeley County near Charleston, South Carolina.

The company said $2.38 million is being invested in the site, which will be a 10,000-square-foot manufacturing operation. It will contain an ISO Class 6 Clean Room that makes up about half of the operating space.

When completed by the second half of this year, the facility is expected to create about 90 new jobs.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We believe that we are surrounding ourselves with an enabling, empowering and conducive team like no other,” Raja Edward Hitti, Med-Ally’s chief executive, said in a statement. “We look forward to growing and prospering in Berkeley County amidst its wonderful constituency and leadership team.”

The VersaStim technology was designed to treats patients with movement disorders, spinal cord injuries, chronic pain and traumatic brain injuries. The device is available in external and implantable systems to maximize therapy effectiveness and improve patient outcomes.

Suggested Articles

The FDA approved a new, tiny pacemaker from Medtronic that does not require the wiring of separate electrodes between the implant and the heart.

The respiratory care company Vyaire Medical has brought on a new CEO, Gaurav Agarwal, following a year of new product launches.

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its platform.